
|Articles|October 1, 2001
Hydroflex II acrylic IOL
The FDA has approved phase I clinicaltrials on Medical Developmental Research Inc.'s Hydroflex II Advanced SeriesHydrophilic Acrylic IOL.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA clears BVI’s FineVision HP trifocal IOL for the US market
2
Treating myopia today: US-focused treatments, challenges, and global insights
3
US FDA awards Epion Therapeutics EpiSmart cross-linking system Fast Track designation
4
Abeona Therapeutics’ ABO-503 chosen for FDA's Rare Disease Endpoint Advancement Pilot Program
5